DE69637156D1 - Dna-molekül, herstellung und verwendung in der gentherapie - Google Patents

Dna-molekül, herstellung und verwendung in der gentherapie

Info

Publication number
DE69637156D1
DE69637156D1 DE69637156T DE69637156T DE69637156D1 DE 69637156 D1 DE69637156 D1 DE 69637156D1 DE 69637156 T DE69637156 T DE 69637156T DE 69637156 T DE69637156 T DE 69637156T DE 69637156 D1 DE69637156 D1 DE 69637156D1
Authority
DE
Germany
Prior art keywords
manufacture
gene therapy
dna molecule
genes
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637156T
Other languages
English (en)
Other versions
DE69637156T2 (de
Inventor
Beatrice Cameron
Joel Crouzet
Anne-Marie Darquet
Daniel Scherman
Pierre Wils
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9476445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69637156(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE69637156D1 publication Critical patent/DE69637156D1/de
Application granted granted Critical
Publication of DE69637156T2 publication Critical patent/DE69637156T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6839—Triple helix formation or other higher order conformations in hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE69637156T 1995-02-23 1996-02-21 Dna-molekül, herstellung und verwendung in der gentherapie Expired - Lifetime DE69637156T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9502117A FR2731014B1 (fr) 1995-02-23 1995-02-23 Molecules d'adn, preparation et utilisation en therapie genique
FR9502117 1995-02-23
PCT/FR1996/000274 WO1996026270A1 (fr) 1995-02-23 1996-02-21 Molecules d'adn, preparation et utilisation en therapie genique

Publications (2)

Publication Number Publication Date
DE69637156D1 true DE69637156D1 (de) 2007-08-23
DE69637156T2 DE69637156T2 (de) 2008-02-07

Family

ID=9476445

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69637156T Expired - Lifetime DE69637156T2 (de) 1995-02-23 1996-02-21 Dna-molekül, herstellung und verwendung in der gentherapie

Country Status (19)

Country Link
US (3) US6143530A (de)
EP (1) EP0815214B1 (de)
JP (1) JPH11500618A (de)
KR (1) KR19980702406A (de)
AT (1) ATE366806T1 (de)
AU (1) AU709111B2 (de)
BR (1) BR9607273A (de)
CA (1) CA2211427C (de)
CZ (1) CZ266897A3 (de)
DE (1) DE69637156T2 (de)
FI (1) FI973467A0 (de)
FR (1) FR2731014B1 (de)
HU (1) HUP9801216A3 (de)
IL (1) IL117214A0 (de)
MX (1) MX9706109A (de)
NO (1) NO973838L (de)
SK (1) SK114397A3 (de)
WO (1) WO1996026270A1 (de)
ZA (1) ZA961484B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428402A1 (de) * 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
IL135776A0 (en) 1997-10-24 2001-05-20 Life Technologies Inc Recombinational cloning using nucleic acids having recombination sites
CN1292827A (zh) * 1998-03-24 2001-04-25 阿文蒂斯药物股份有限公司 核酸转移载体、含有它们的组合物及其应用
FR2776669B1 (fr) * 1998-03-24 2001-06-15 Rhone Poulenc Rorer Sa Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations
US6632672B2 (en) * 1998-08-19 2003-10-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for genomic modification
US6410241B1 (en) 1999-03-24 2002-06-25 Board Of Regents, The University Of Texas System Methods of screening open reading frames to determine whether they encode polypeptides with an ability to generate an immune response
US6746870B1 (en) * 1999-07-23 2004-06-08 The Regents Of The University Of California DNA recombination in eukaryotic cells by the bacteriophage PHIC31 recombination system
DE19941186A1 (de) * 1999-08-30 2001-03-01 Peter Droege Sequenz-spezifische DNA-Rekombination in eukaryotischen Zellen
ES2245656T3 (es) * 1999-12-30 2006-01-16 Aventis Pharma S.A. Utilizacion de un vector que comprende un acido nucleico que codifica un factor anti-angiogeno para el tratamiento de las neovascularizaciones de la cornea.
FR2803207B1 (fr) * 1999-12-30 2004-04-30 Aventis Pharma Sa Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
BR0111145B1 (pt) * 2000-05-26 2013-06-04 mÉtodos para purificar dna de filamento duplo a partir de uma soluÇço contendo o dna de filamento duplo misturado com outros componentes.
AU2001277076A1 (en) * 2000-07-21 2002-02-05 The United States Of America As Represented By The Secretary Of Agriculture Methods for the replacement, translocation and stacking of DNA in eukaryotic genomes
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
FR2822476B1 (fr) * 2001-03-23 2004-04-02 Aventis Pharma Sa Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice
CA2440133A1 (fr) * 2001-03-23 2002-10-03 Gencell S.A. Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice
US7138267B1 (en) 2001-04-04 2006-11-21 Epicentre Technologies Corporation Methods and compositions for amplifying DNA clone copy number
AU2002247848A1 (en) * 2001-04-10 2002-10-28 Imperial College Innovations Limited Methods for the production of minicircles
GB0108968D0 (en) * 2001-04-10 2001-05-30 Imp College Innovations Ltd Methods
NZ545697A (en) * 2001-05-30 2008-06-30 Glaxo Group Ltd A lambda-intR mutein comprising a glutamic acid to arginine change at position 174 of Wt lambda-intR
AU2002325346A1 (en) 2001-07-05 2003-01-21 Aventis Pharma S.A. Method of administration of a gene of interest to the heart and vasculature
US20030108524A1 (en) * 2001-10-18 2003-06-12 Melissa Diagana Vectors for expressing multiple transgenes
AU2003242459B2 (en) 2002-06-18 2007-05-17 Eisai R&D Management Co., Ltd. Primary cultured adipocytes for gene therapy
JP2006515162A (ja) 2002-08-29 2006-05-25 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 環状核酸ベクター、ならびに同ベクターの作製法および使用法
CA2498518A1 (en) * 2002-09-13 2004-03-25 Valentis, Inc. Apparatus and method for preparative scale purification of nucleic acids
US20040166512A1 (en) * 2002-11-12 2004-08-26 Kahn Michael L. Method for cloning PCR products without restriction or ligation enzymes
AT412400B (de) 2003-05-08 2005-02-25 Mayrhofer Peter Mag Dr Minicircle-herstellung
DE50305146D1 (de) * 2003-06-10 2006-11-02 Mologen Ag Zirkuläres expressionskonstrukt für gentherapeutische anwendungen
WO2005054438A2 (en) 2003-12-01 2005-06-16 Invitrogen Corporation Nucleic acid molecules containing recombination sites and methods of using the same
US20060046294A1 (en) * 2004-08-26 2006-03-02 The United States Of America, As Represented By The Secretary Of Agriculture Site-specific recombination systems for use in eukaryotic cells
IL165365A0 (en) 2004-11-24 2006-01-15 Q Core Ltd Finger-type peristaltic pump
US9018012B2 (en) * 2005-01-20 2015-04-28 Nature Technology Corporation Vectors and methods for genetic immunization
EP1882036B1 (de) * 2005-05-17 2012-02-15 Ozgene Pty Ltd Sequentielles klonierungssystem
US20070212337A1 (en) * 2006-02-01 2007-09-13 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
AU2008283802A1 (en) * 2007-07-31 2009-02-05 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
US8945885B2 (en) 2008-07-03 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
EP2304025B1 (de) * 2008-07-03 2015-11-04 The Board of Trustees of the Leland Stanford Junior University Minicircle-dna-vektorpräparationen und verfahren zur herstellung und verwendung davon
DE102009054265A1 (de) 2009-11-16 2011-05-26 Giese, Matthias, Dr. Orale Verabreichung von DNA an Insekten
WO2011057825A1 (en) 2009-11-16 2011-05-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Induction of gene expression in arthropods
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
GB201307075D0 (en) 2013-04-19 2013-05-29 Mayrhofer Peter Plasmid for minicircle production
DE102013220859B4 (de) 2013-10-15 2016-09-08 Plasmidfactory Gmbh & Co. Kg Minicircles mit viralen Expressionskassetten und ihre Verwendung zur Transformation von Zellen zur Erzeugung rekombinanter Viren oder viraler Genvektoren
EP4031168A4 (de) 2019-09-18 2023-10-11 Intergalactic Therapeutics, Inc. Synthetische dns-vektoren und verwendungsverfahren

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028530A (en) * 1985-01-28 1991-07-02 Xoma Corporation AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
ATE83008T1 (de) * 1987-07-21 1992-12-15 Du Pont Merck Pharma Verfahren fuer die herstellung von in tierischen zellen stabilen und lebensfaehigen rekombinanten viralen vektoren.
FR2631634B1 (fr) * 1988-05-18 1991-06-14 Centre Nat Rech Scient Vecteurs de clonage et d'expression dans une souche d'actinomycete, procede de transformation de cette souche, souche d'actynomycete obtenue et preparation de proteines
US5227288A (en) * 1990-10-01 1993-07-13 Blattner Frederick R DNA sequencing vector with reversible insert
DE69333823T2 (de) * 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
US5401632A (en) * 1992-07-16 1995-03-28 Wisconsin Alumni Research Foundation Triple helix purification and sequencing
AU5405994A (en) * 1992-10-16 1994-05-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Supercoiled minicircle dna as as a unitary promoter vector
DE19502584C2 (de) * 1994-01-28 1999-08-12 Medigene Ag Ges Fuer Molekular Verfahren zur Bestimmung der Aktivität eines regulatorischen Faktors sowie Verwendung dieses Verfahrens
FR2715940B1 (fr) * 1994-02-10 1996-04-26 Pasteur Merieux Serums Vacc Procédé de préparation d'une banque multicombinatoire de vecteurs d'expression de gènes d'anticorps, banque et systèmes d'expression d'anticorps "coliclonaux" obtenus.
DE4428402A1 (de) * 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy

Also Published As

Publication number Publication date
ZA961484B (en) 1996-08-28
FR2731014A1 (fr) 1996-08-30
IL117214A0 (en) 1996-06-18
EP0815214B1 (de) 2007-07-11
US6143530A (en) 2000-11-07
NO973838L (no) 1997-10-13
KR19980702406A (ko) 1998-07-15
JPH11500618A (ja) 1999-01-19
ATE366806T1 (de) 2007-08-15
FI973467A (fi) 1997-08-22
MX9706109A (es) 1997-11-29
BR9607273A (pt) 1998-07-21
SK114397A3 (en) 1998-02-04
EP0815214A1 (de) 1998-01-07
US20030104444A1 (en) 2003-06-05
AU4882296A (en) 1996-09-11
DE69637156T2 (de) 2008-02-07
CA2211427C (fr) 2010-12-14
CZ266897A3 (en) 1997-11-12
CA2211427A1 (fr) 1996-08-29
FI973467A0 (fi) 1997-08-22
HUP9801216A2 (hu) 1998-08-28
NO973838D0 (no) 1997-08-20
AU709111B2 (en) 1999-08-19
WO1996026270A1 (fr) 1996-08-29
HUP9801216A3 (en) 2001-08-28
US6492164B1 (en) 2002-12-10
FR2731014B1 (fr) 1997-03-28

Similar Documents

Publication Publication Date Title
DE69637156D1 (de) Dna-molekül, herstellung und verwendung in der gentherapie
DE69638183D1 (de) Verwendung von nukleinsäureliganden in der durchflusszytometrie
WO2001002568A3 (en) Human genes and gene expression products
ATE167680T1 (de) Pteridin-nukleotidderivate als fluoreszierende sonden
DE69128893T2 (de) Genetische veränderung von endothelzellen
NO973685L (no) Multi-tumor avvikende vekstgener
DE69432934D1 (de) Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
DE69901177T2 (de) Platinkomplex, dessen herstellung und dessen therapeutische verwendung
DE69736840D1 (de) Synthese von nukleosiden und polynukleotiden
ATE431405T1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
DE69638166D1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
DE69614668D1 (de) Medizinische zusammensetzung zur verwendung für die transfektion und in vivoexpression von exogenen
FI925359A0 (fi) Kloning och expression av dna-molekyler, som kodar foer arabinandegraderande enzymer av svampursprung
DE69532485D1 (de) Trehalose-freisetzendes Enzym, dafür kodierende DNA, Herstellung und Verwendung
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
DK0877758T3 (da) Oprenset SR-p70-protein
DE69130845D1 (de) HLA-DR Antigen-Gen, dessen Nukleotidsequenz und Verwendung
DE69733948D1 (de) In vivo herstellung von replicativen molekülen
WO2001098350A3 (en) Compositions comprising net-4 modulations and their use for treating neoplastic disease
MX9709596A (es) Adn catal ??tico.
DE60024442D1 (de) Verwendung von viralen vektoren und geladenen molekülen für die gentherapie

Legal Events

Date Code Title Description
8363 Opposition against the patent